Medizinische Universität Graz - Research portal
Selected Publication:
Paridaens, R; Van Aelst, F; Georgoulias, V; Samonigg, H; Cocquyt, V; Zielinski, C; Hausmaninger, H; Willemse, P; Boudraa, Y; Wildiers, J; Ramazeilles, C; Azli, N.
A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
ANN ONCOL. 2003; 14(3): 433-440.
Doi: 10.1093/annonc/mdg111
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with MBC requiring first-line chemotherapy for progressive disease (n = 106) were randomized and received 3-weekly monotherapy with docetaxel (T, 100 mg/m2, 1-h i.v. infusion) and doxorubicin (A, 75 mg/m2, 20-30-min i.v. infusion) either on a cycle-by-cycle alternating basis (ATATATAT, n = 51) or sequentially each for four cycles (TTTTAAAA, n = 55). RESULTS: For both regimens, the median number of cycles administered was the maximum of eight. The alternating and sequential groups achieved similar objective tumor response rates (60% and 67%, respectively) and similar median duration of response (47 and 44 weeks, respectively). With a median follow-up of 31 months, median survival times were estimated at 20 and 26 months in the alternating and sequential groups, respectively. No unexpected toxicities were reported. Compared with alternating therapy, patients receiving sequential therapy were more likely to complete the planned eight chemotherapy cycles (69% versus 63%), and had a lower incidence of febrile neutropenia (2% versus 14%). CONCLUSIONS: Alternating and sequential docetaxel-doxorubicin regimens are viable alternatives to simultaneous combination therapy in MBC, with sequential therapy achieving slightly higher response rates and improved tolerability compared with alternating therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - administration and dosage
- Breast Neoplasms - drug therapy
- Doxorubicin - administration and dosage
- Drug Administration Schedule - administration and dosage
- Female - administration and dosage
- Humans - administration and dosage
- Middle Aged - administration and dosage
- Neoplasm Metastasis - administration and dosage
- Neutropenia - chemically induced
- Survival Analysis - chemically induced
- Taxoids - administration and dosage
- Find related publications in this database (Keywords)
- alternating
- breast cancer
- chemotherapy
- docetaxel
- doxorubicin
- sequential